Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Binge Eating Disorder Pipeline Review, H2 2018 - Therapeutic Analysis of 7 Companies & Drug Profiles - ResearchAndMarkets.com

Research and Markets
Posted on: 19 Oct 18

The "Binge Eating Disorder - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Binge Eating Disorder - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 6 respectively.

Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Binge Eating Disorder - Overview
  4. Binge Eating Disorder - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Binge Eating Disorder - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Binge Eating Disorder - Companies Involved in Therapeutics Development
  • Chronos Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Heptares Therapeutics Ltd
  • Novo Nordisk AS
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Sunovion Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6sbr3q/binge_eating?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005628/en/

Business Wire
www.businesswire.com

Last updated on: 19/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.